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Abstract 
Background: Tumour necrosis factor (TNF) is central to the immune response to Plasmodium infection. Its plasma 
concentration is influenced by allele variants in the promoter region of TNF. The study’s objectives were to assess TNF 
allele variants (TNF−1031, TNF−308): (1) modulation of malaria rates in young Tanzanian children; (2) modulation of the 
severity of malaria as indicated by haemoglobin concentrations at the time of presentation with febrile episodes; and 
(3) the association between Plasmodium infection and haemoglobin concentration in symptomless parasite carriers.
Methods: Data from a placebo‑controlled trial in which 612 Tanzanian children aged 6–60 months with height‑for‑
age z‑score in the range −3 SD to 1.5 SD was utilised. Those with Plasmodium infection at baseline were treated with 
artemether‑lumefantrine. An episode of malaria was predefined as current Plasmodium infection with an inflamma‑
tory response (axillary temperature ≥37.5°C or whole blood C‑reactive protein concentration ≥8 mg/L) in children 
reported sick. Linkage disequilibrium (LD) pattern assessment as well as haplotype analysis was conducted using 
HAPLOVIEW. Cox regression models used in the primary analysis accounted for multiple episodes per child.
Results: Genotyping of 94.9% (581/612) children for TNF−1031 (TNF−1031T>C); allele frequency was 0.39. Corre‑
sponding values for rs1800629 (TNF−308G>A) were 95.4% (584/612) and 0.17. Compared to the wild type genotype 
(TT), malaria rates were increased in the TNF−1031CC genotype (hazard ratio, HR [95% CI]: 1.41 [1.01‒1.97] and 1.31 
[0.97‒1.76] for crude analysis and adjusting for pre‑specified baseline factors, respectively) but decreased in those 
with the TNF−308AA genotype (corresponding HR: 0.13 [0.02‒0.63] and 0.16 [0.04‒0.67]). These associations were 
weaker when analysing first episodes of malaria (P value −0.59 and 0.38, respectively). No evidence that allele variants 
of TNF−1031 and TNF−308 affected haemoglobin concentration at first episode of malaria, or that they modified the 
association between Plasmodium infection and haemoglobin concentrations at baseline was observed.
Conclusion: In this cohort of Tanzanian children, the TNF−1031CC genotype was associated with increased rates of 
malarial episodes, whereas the TNF−308AA genotype was associated with decreased rates.
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Background
Tumour necrosis factor (TNF) is central to the immune 
response to Plasmodium infection because of its 
pyrogenic properties and its key role in triggering the 
cascade of pro-inflammatory cytokines that regulate 
immune cells. It is secreted predominantly by activated 
macrophages following exposure to Plasmodium anti-
gens, and acts to suppress parasitaemia.
Eight variants have been described within the TNF 
promoter at positions 1031T>C (rs1799964), −863C>A 
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(rs1800630), −857C>T (rs1799724), −575G>A, −376G>A 
(rs1800750), −308G>A (rs1800629), −244G>A, and 
−238G>A (rs361525) relative to the transcription start site 
[1–7]. These genetic variants are investigated due to the 
possibility that the genetic changes they introduce, in com-
parison to the wild type form, could affect the binding of 
transcription factors, thereby controlling the activity of the 
promoter sites and affecting resulting mRNA and protein 
concentrations. There are many studies showing associa-
tion of TNF variants with various infectious diseases, but 
others failed to show an association [8].
In relation to malaria, the TNF−1031C allele has been 
associated with decreased risk of severe malaria in a child 
cohort of Gambian malaria patients but this observation 
was not made in similar cohorts from Kenya and Malawi 
[9]. Also observations from a case–control study in India 
indicate that the TNF−1031C allele is associated with ele-
vated plasma TNF concentrations and increased suscep-
tibility to severe falciparum malaria [10]. TNF−308AA has 
been associated with severe cerebral malaria in Gambian 
children, and with a seven-fold increased risk of death 
and severe cerebral malaria [11]. Furthermore, a study of 
Gabon school children observed the TNF−308A allele to 
be associated with shorter intervals of malaria reinfection 
[12]. A Kenyan study investigating malarial morbidity in 
young children found this variant to be associated with 
preterm birth and early childhood mortality and malaria 
morbidity, with carriers showing a trend towards high 
density parasitaemia and severe malarial anaemia [13]. 
Another study from Sri Lanka found that the TNF−308AA 
was associated with both severe malaria and other infec-
tions [14]. Some studies however have failed to observe 
any association between TNF−308AA and malaria. A 
study of malaria patients from Thailand found no asso-
ciation between TNF−308AA and disease severity. This 
finding is similar to that of Ubalee et al. [15], which did 
not observe a difference in severe symptoms between 
patients in Myanmar on the basis of TNF−308AA [15]. 
Another study of Tanzanian infants observed minor clin-
ical parameters to differ in TNF−308GA heterozygotes but 
did not observe major differences in other malaria related 
indices [16].
There have been few cohort studies to longitudinally 
assess the association of TNF allele variants on malaria 
outcomes. Children with an elevated TNF response to 
Plasmodium infection are more likely to become sicker 
than their peers with a lower TNF response capacity, so 
that the former may experience more frequent episodes 
of malaria. On the other hand, in children exposed to 
chronic or repeated Plasmodium infections, an increased 
TNF response associated with the TNF−308AA geno-
type may intensify a hepcidin-mediated block in iron 
absorption and consequently induce or exacerbate iron 
deficiency [17], which probably protects against malarial 
episodes [18, 19].
The aim of this study was therefore to assess the asso-
ciations of TNF−1031 and TNF−308 allele variants with 
malaria rates in young Tanzanian children. Additionally, 
the study aimed to investigate the association of these 
variants on the severity of malaria as indicated by hae-
moglobin concentrations at the time of presentation with 
febrile episodes. Lastly, how these variants modulated 
the association between Plasmodium infection and hae-
moglobin concentration in symptomless parasite carriers 
was assessed.
Methods
Study area and population
Data from a randomized trial that aimed to assess the 
effect of supplementation with zinc and other micro-
nutrients on malaria rates was used. The trial was con-
ducted between February 2008 and March 2009 in four 
rural villages in Handeni District, northeastern Tan-
zania. Residents primarily belong to the Wazigua and 
Wabondei Bantu tribes, but settlement of migrant planta-
tion workers has resulted in a mixture of tribes with dif-
ferent origins and much intermarriage. The area is mainly 
populated by poor farmer families involved in subsist-
ence farming. Malaria transmission is intense and peren-
nial, with nearly all infections being due to Plasmodium 
falciparum [20]. Apart from several local traditional heal-
ers, the research dispensary was the only health facil-
ity in the area. The study was approved by the Ethical 
Review Committee of Wageningen University, The Neth-
erlands (Approval number: NL: 04/07) and the National 
Health Research Ethics Review sub-Committee, Dar es 
Salaam, Tanzania (Approval number: NIMR/HQ/R.8a/
Vol. IX/540). Informed consent was obtained from com-
munity leaders, local government officials and parents or 
guardians. Further details of this trial are described else-
where [21].
Recruitment
All resident children were eligible for randomization 
when aged 6–59  months and with a height-for-age 
z-score in the range −3 SD to 1.5 SD. Children with hae-
moglobin concentration <70 g/L, signs of chronic illness, 
and those unlikely to remain permanently resident or 
comply with the supplementation for the duration of the 
trial, or whose parents or guardians declined consent, 
were excluded from the study. Venous blood samples 
were collected in EDTA tubes and centrifuged imme-
diately. An aliquot of 90 μL erythrocyte sediment with 
the buffy coat was mixed with 90 μL phosphate-buffered 
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saline and 180  μL of DNA stabilizing buffer (AS1; 
Qiagen, Hilden, Germany) and stored at 4°C for sub-
sequent genotyping. Plasma samples were stored in 
liquid nitrogen in the field and at −80°C during trans-
port and subsequent storage until biochemical analysis 
in The Netherlands. Haemoglobin concentration was 
measured in an aliquot of whole blood by a haematol-
ogy analyser (Sysmex KX21, Kobe, Japan). Plasmodium 
infection was detected in fresh blood by rapid dipstick 
test (CareStart, Access Bio, Monmouth Jct, USA). Chil-
dren with a positive test result were treated immediately 
with artemether-lumefantrine. The location of the child’s 
homestead was determined using a global positioning 
system. Further details about recruitment procedures 
are reported elsewhere [21].
Experimental intervention
Children were randomized within six strata defined 
by Plasmodium infection (binary) and age class 
(6–17  months, 18–35  months and 36–60  months) and 
randomly permuted blocks with size randomly selected 
of four or eight. They then received daily supplements 
with either zinc alone (10 mg as gluconate), multi-nutri-
ents without zinc, zinc combined with multi-nutrients 
or placebo. Supplements, in the form of powder in col-
our-coded capsules, were contained in blister packs, and 
administered orally after suspending capsule contents 
in clean water or breastmilk. Supplementation was per-
formed by local community volunteers, who reported 
adherence daily to field staff at the research dispensary.
Follow‑up and case detection
A clinical officer was on duty at the research clinic day 
and night. At recruitment, parents or guardians were 
requested to bring participating children to the dis-
pensary immediately when detecting fever or any other 
illness during the intervention period. In samples col-
lected at baseline and from sick children, the presence 
of parasite-specific lactate dehydrogenase (P. falcipa-
rum and other Plasmodium species) was detected by 
rapid tests (CareStart, G0121, Access Bio, Monmouth 
Jct, NJ). Axillary temperature was measured using an 
electronic thermometer and dipstick tests were admin-
istered for children with guardian-reported fever; for 
those with positive test results, plasma samples were 
collected and measured whole-blood C-reactive pro-
tein concentrations using a point-of-care test. Plasma 
was stored as described for the recruitment procedure. 
Artemether-lumefantrine (Novartis Pharma, Basel, 
Switzerland) was administered to any child with cur-
rent Plasmodium infection upon enrolment, or with 
reported fever and a positive dipstick test result during 
the follow-up period.
Laboratory procedures
For children who presented with malarial episodes, 
whole-blood concentrations of haemoglobin and C-reac-
tive protein were measured using point-of-care tests 
(HemoCue, Ängelholm, Sweden and QuikRead, Orion 
Diagnostica, Espoo, Finland, respectively). Plasma con-
centrations of P. falciparum-specific histidine-rich 
protein-2 (HRP2) in samples collected during the first 
malaria episode were measured using a commercial 
enzyme-linked immunosorbent assay kit (Malaria Ag 
Celisa; Cellabs, Brookvale, NSW, Australia). Plasma con-
centrations of C-reactive protein were measured (Mean-
der Medical Centre, Amersfoort, The Netherlands) on a 
Beckman Coulter Unicel DxC880i system according to 
the manufacturer’s instructions. Genotypes were deter-
mined using Illumina’s VeraCode™ GoldenGate Genotyp-
ing Assay on a BeadXpress™ platform. TNF variant allele 
clustering was assessed visually to determine success of 
genotyping. Further quality control cut-offs were: a Gen-
Call Score of >0.5 and a call rate of ≥0.95 [22]. For the 
variant TNF−1031, the reference allele was T and the alter-
nate C. Individuals homozygous for the TNF−1031 refer-
ence allele (T) are hereon described as wild type while 
those homozygous for the alternate allele (C) are referred 
to as homozygote mutant. For the variant TNF−308, the 
reference allele was G and the alternate was A. Individu-
als homozygous for the TNF−308 reference allele (G) are 
hereon described as wild type while those homozygous 
for the alternate allele (A) are referred to as homozygote 
mutant.
Statistical analyses
Linkage disequilibrium (LD) pattern assessment as well 
as haplotype analysis was conducted using HAPLOV-
IEW [23]. Anthropometric indices were calculated using 
Epi Info software [24] All analyses were performed using 
SPSS (v15.0 for Windows, SPSS, Chicago, IL, USA), CIA 
(v2.1.2) [25] and STATA (v11; College Station, TX, USA). 
For each TNF genotype, Fisher’s exact test was used to 
assess whether populations were in Hardy–Weinberg 
equilibrium. The differences in baseline characteristics 
were calculated using the homozygote wild-type group 
as the reference for each variant using CIA (v2.1.2). 
Normality of variables was assessed by visual inspection 
of histograms. Because variables of interest (age, hae-
moglobin concentrations, distance from homestead to 
dispensary and anthropometric indices) were normally 
distributed, means, SDs and 95% CIs were reported.
Association of TNF genotype with malaria rates
The primary outcome, an episode of malaria, was pre-
defined as a positive result for either a pLDH or a HRP2 
dipstick test with any of the following: (a) confirmed 
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fever (axillary temperature ≥37.5°C as measured by 
electronic thermometer); or, (b) guardian-reported but 
unconfirmed 24-h history of fever in the presence of 
inflammation (whole blood C-reactive protein concen-
trations >8 mg/L), separated by at least 14 days from a 
previous malaria episode. Incidence per TNF genotype 
and incidence ratios based on time to first episodes, 
with wild-type homozygotes as reference group was 
calculated. In the primary analysis, group rates were 
compared using Cox regression with robust estimates 
of the standard error to account for multiple episodes 
within children. The extent to which supplementa-
tion with either zinc or multi-nutrients including iron 
modulated the magnitude of the association of TNF 
genotype on malaria rates was explored. The extent to 
which adjustment for baseline factors that were a pri-
ori expected to be prognostic for malaria (Plasmodium 
infection status, distance between homestead and clinic 
[continuous variable], height-for-age z-score [continu-
ous variable], mosquito net use [binary variable]) and 
experimental intervention modulated the estimated 
association of genotypes were explored. In this adjusted 
analysis, experimental intervention as a binary vari-
able indicating pooled groups receiving multi-nutrients 
(with or without zinc) and pooled groups receiving no 
multi-nutrients (with or without zinc) was included. 
Kaplan–Meier analysis with Peto tests were used to 
assess associations of TNF genotypes with time-to-first 
episode of malaria.
TNF genotype modulation of the association 
between Plasmodium falciparum infection 
and haemoglobin concentration at baseline
Since the additive genetic model was considered, for each 
genotype, two dummy variables were used to indicate 
the three classes, resulting in two interaction terms per 
variant. Regression models were then used to assess the 
modulation of genotypes on the associations between 
P. falciparum and haemoglobin concentration. Main 
terms for P. falciparum infection and genotype dummies 
were included, and adjusted as pre planned for age class, 
mosquito net use, height-for-age z-score, and distance 
between the child’s homestead and the dispensary in 
regression analyses.
TNF genotype modulation of the association 
between Plasmodium falciparum infection 
and haemoglobin concentration at first episode of malaria
The additive genetic model was considered so for each 
genotype, two dummy variables were used to indicate 
the three classes. TNF genotype modulation of the asso-
ciation between P. falciparum infection and haemoglobin 
concentration at first episode of malaria was then 
assessed by analysis of variance (ANOVA) and adjusted 
for age class, height-for-age z-score and distance between 
the child’s homestead and the dispensary and treatment 
group.
Results
Of 612 children recruited in the original study, 581 
(94.9%) and 584 (95.4%) had DNA typed for TNF−1031 
and TNF−308, respectively. Only 3% (20/612) of children 
failed to complete the trial. Minor allele frequencies were 
0.39 (TNF−1031) and 0.17 (TNF−308), respectively. Neither 
of the TNF variants showed a departure from Hardy–
Weinberg equilibrium (P  =  0.90 and 0.57 for TNF−1031 
and TNF−308, respectively). Additionally, the variants 
TNF−1031 is not in linkage disequilibrium with TNF−308 
(r2 = 0.03). No haplotype blocks were identified.
Baseline factors associated with TNF genotypes
Children with TNF−1031C allele seemed to have larger 
weight-for-age z-scores than their peers with the wild 
type variant (0.14 SD and 0.41 SD in heterozygotes 
and homozygotes, respectively, compared to −0.18 SD 
in those with the wild type genotype) (Table  1). The 
TNF−308A allele was marginally significantly associated 
with increased Plasmodium infection, but the evidence 
was weak (p-value: 0.09). No evidence of other factors 
being associated with the TNF genotypes investigated 
was observed.
Associations of TNF genotype with malaria rates
Overall, there were 1,511 malaria episodes recorded in 
400 child-years of observation (incidence: 3.8/child-
year). Of 581 children, 489 children (84%) experienced 
at least one malaria episode while recurrent episodes 
occurred in 406 (69%) children (Table  2). Compared to 
the wild type genotype, malaria rates (all episodes) in 
homozygotes for the TNF−1031C allele (TNF−1031CC) 
were elevated by 41% (hazard ratio 1.41; crude analysis). 
In the analysis of first episodes, malaria rates also seemed 
elevated for this genotype (hazard ratio 1.17, Table 2), but 
the statistical evidence for such an association was much 
weaker (P = 0.59). Only one episode of malaria occurred 
in homozygotes for the TNF−308A allele (TNF−308AA). 
This genotype was nonetheless associated with a 
decrease in malaria rates by 87% (hazard ratio 0.13; all 
episodes). Malaria rates were similarly decreased in the 
analysis of first episodes, but the statistical evidence was 
weak (P = 0.38). Kaplan–Meier analysis did not indicate 
marked group-specific differences in malaria rates for 
specific time periods of follow-up for either of the two 
TNF genotypes investigated (Figure 1).
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Associations of TNF genotype with haemoglobin 
concentration at first malarial episode
No evidence that haemoglobin concentrations at first 
episode of malaria varied by variants of TNF−1031 was 
observed (Figure 2).
TNF genotype modulation of the association 
between Plasmodium infection and haemoglobin 
concentration at baseline
No evidence that heterozygosity for either TNF−1031 or 
TNF−308 modified the association between Plasmodium 
infection at baseline and haemoglobin concentra-
tions at baseline (p-values: 0.47 and 0.57, respectively) 
was observed. Similarly, no evidence that this asso-
ciation was modified by homozygosity for TNF−1031C 
(p-value = 0.56) was found (Figure 3).
Discussion
In this cohort of Tanzanian children, malaria rates due 
to P. falciparum were increased in homozygotes for 
the TNF−1031C allele (TNF−1031CC) and decreased in 
homozygotes for the TNF−308A allele (TNF−308AA). No 
Table 1 Factors associated with rs1799964 and rs1800629 allele variants of the TNF gene
Reference/wild type allele for TNF−1031 is T and TNF−308 is G. For both genotypes the reference/wild type allele is the common allele. p‑values for the associations 
between each factor and the allele variants investigated. Mean ± SD or % [n] unless indicated otherwise % figures represent % with feature/% without feature (num‑
ber with feature/number without feature). Difference is relative to the wild type group. The difference columns are for each variable a comparison of the heterozy‑
gotes and the homozygote mutants to the wild type.
a Haemoglobin concentration <110 g/L.
b Plasma C‑reactive protein concentration ≥8 mg/L.
c Data missing for 11 children.
d As the crow flies, based measurements by global positioning system.
Allele variant/factor Wild type Heterozygote Difference (95% CI) Homozygote  
mutant
Difference (95% CI) p‑value
rs1799964 −1031TT −1031TC −1031CC
 n 356 200 25
 Age (months) 33.4 ± 15.5 31.9 ± 16.1 −1.5 (−4.2,1.2) 28.06 ± 14.9 −5.3 (−11.6, 0.99) 0.18
 Sex (%male) 48.0% (171) 48.0% (96) 0.0% (−8.6%, 8.6%) 44.0% (11) −4.0% (−22.1%, 15.6%) 0.93
 Haemoglobin concentration, g/L 102.7 ± 12.3 103.4 ± 13.8 0.0 (−2.1,2.1) 101.5 ± 10.4 −1.2 (−6.2, 3.8) 0.71
 Anaemia, % (n)a 69.1% (246) 66.0% (132) −3.1% (−11.3%, 4.9%) 76.0% (19) 6.9% (−13.1%, 20.4%) 0.50
 Plasmodium infection, % (n) 43.8% (156) 43.0% (86) −0.8% (−9.3%, 7.8%) 36.0% (9) −7.8% (−24.4%, 12.3%) 0.75
 Inflammation, % (n)b 32.3% (114) 32.0% (64) 0.0% (−7.9%, 8.2%) 32.0% (8) −0.3% (−15.6%, 19.8%) 0.58
 Mosquito net use, % (n)c 32.9% (117) 32.0% (64) −0.1% (−8.8%, 7.3%) 32.0% (8) −0.9% (−16.5%, 19.3%) 0.99
 Distance from homestead to 
dispensary, kmd
3.5 ± 2.1 3.5 ± 2.2 0.0 (−0.4, 0.4) 3.8 ± 2.6 0.3 (−0.6, 1.2) 0.90
 Anthropometric indices
  Height‑for‑age z‑score −2.45 ± 0.70 −2.38 ± 0.69 0.07 (−0.05, 0.19) −2.48 ± 0.78 −0.03 (−0.32, 0.26) 0.48
  Weight‑for‑height z‑score −0.18 ± 0.81 −0.04 ± 0.85 0.14 (0.00, 0.28) 0.23 ± 1.00 0.41 (0.08, 0.75) 0.02
  Weight‑for‑age z‑score −1.63 ± 0.74 −1.52 ± 0.75 0.11 (−0.02, 0.24) −1.42 ± 0.76 0.21 (−0.09, 0.51) 0.13
rs1800629 −308GG −308GA −308AA
 n 477 104 3
 Age 32.1 ± 15.7 34.8 ± 15.3 2.7 (−0.6, 6.0) 47.08 ± 11.7 15.0 (−2.9, 32.8) 0.08
 Sex (% male) 46.8% (223) 53.8% (56) 7% (−4%, 17%) 66.7% (2) 20% (−26%, 48%) 0.34
 Haemoglobin concentration, g/L 102.3 ± 12.8 105.2 ± 12.2 2.9 (0.2, 5.6) 105.0 ± 19.2 2.7 (−11.9, 17.3) 0.10
 Anaemia, % (n)a 69.0% (329) 64.4% (67) −4.5% (−14.9%, 5.0%) 66.7% (2) −2.3% (−48.4%, 25.2%) 0.54
 Plasmodium infection, % (n) 41.1% (196) 51.9% (54) 10.8% (0.3%, 21.1%) 66.7% (2) 25.6% (−20.5%, 53.1%) 0.09
 Inflammation, % (n)b 31.0% (148) 33.7% (35) 2.6% (−6.8%, 12.9%) 33.3% (1) 2.3% (−25.2%, 48.4%) 0.23
 Mosquito net use, % (n)c 32.9% (157) 30.8% (32) −2.1% (−11.3%, 8.1%) 33.3% (1) 0.4% (−27.1%, 46.5%) 0.95
 Distance from homestead to 
dispensary, kmd
3.6 ± 2.2 3.6 ± 2.2 0.0 (−0.5, 0.5) 3.5 ± 1.0 −0.10 (−2.6, 2.4) 1.00
 Anthropometric indices
  Height‑for‑age z‑score −2.42 ± 0.69 −2.47 ± 0.74 −0.05 (−0.20, 0.10) −2.69 ± 0.72 −0.27 (−1.06, 0.52) 0.61
  Weight‑for‑height z‑score −0.11 ± 0.84 −0.17 ± 0.85 −0.06 (−0.24, 0.12) 0.07 ± 0.78 0.04 (−0.92, 1.00) 0.73
  Weight‑for‑age z‑score −1.57 ± 0.75 −1.64 ± 0.75 −0.07 (−0.23, 0.09) −1.56 ± 0.92 0.01 (−0.84, 0.86) 0.72
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evidence that allele variants of TNF−1031 and TNF−308 
were associated with haemoglobin concentration at first 
episode of malaria, or that they modified the association 
between Plasmodium infection and haemoglobin con-
centrations at baseline was found.
The associations between TNF allele variants and 
malaria rates were generally more pronounced in the 
analysis of all episodes than in the analysis of first epi-
sodes (Table  2). The question arises how such differ-
ences should be interpreted. Some children experience 
malaria more frequently than others. This between-indi-
vidual variation may be due to differences in exposure to 
infectious mosquito bites, immunity (and thus age) and 
therapy-seeking behaviour. In the presence of such het-
erogeneity in susceptibility to malaria, ‘high risk’ indi-
viduals tend to become sick more rapidly than ‘low risk’ 
individuals, and once they have experienced an episode 
they are no longer considered in a time-to-first-event 
analysis. With the passing of follow-up time, only the ‘low 
risk’ individuals remain in the risk set and, accordingly, 
the event rate observed will decrease. In cohort studies 
such as the one described herein, this decrease is gener-
ally more pronounced in groups with high overall event 
rates, which have ‘high-risk’ individuals dropping out 
more efficiently. In a time-to-first-event analysis, group 
contrasts can become underestimated and associations 
with malaria may appear decrease with time. For this rea-
son, the analysis of all episodes reflects with more valid-
ity associations between TNF allele variants and malaria 
rates than analysis of first episodes. In addition, the for-
mer better reflects associations with the total population 
burden of disease.
There was no evidence that the association between 
TNF−1031CC genotype and malaria rates were con-
founded by Plasmodium infection status, distance 
between homestead and clinic, height-for-age z-score 
and mosquito net use factors assessed at baseline, or 
by the experimental intervention. Similarly, no evi-
dence for such confounding on the association between 
TNF−308AA and malaria rates was found. These asso-
ciations should nonetheless be interpreted with caution, 
because the statistical evidence was weak in the analysis 
of first episodes, even though the direction of these asso-
ciations was similar.
The observation that TNF−1031CC genotype was associ-
ated with increased malaria rates whilst the TNF−308AA 
Table 2 Associations between TNF genotype and rates of first and all episodes of malaria
Values between brackets indicate (episodes/child‑years observed) or [95% CIs].
a Estimates adjusted for baseline Plasmodium infection status, distance between homestead and clinic (continuous variable), height‑for‑age z‑score (continuous vari‑
able), mosquito net use and experimental intervention. There was no evidence of interactions between genotype and experimental intervention.
Homozygotes Heterozygotes Homozygote mutants
rs1799964 −1031TT −1031TC −1031CC
 All episodes of malaria
  n 356 200 25
  Incidence 2.93 (907/309.1) 2.92 (502/171.9) 4.15 (90/21.7)
  Hazard ratio, crude 1.00 Reference 0.99 [0.85–1.14] 1.41 [1.01–1.97]
  Hazard ratio, adjusteda 1.00 Reference 0.95 [0.82–1.09] 1.35 [1.01–1.80]
 First episode of malaria
  Incidence 2.85 (296/104.0) 3.09 (168/54.4) 3.29 (20/6.07)
  Incidence ratio 1.00 Reference 1.08 [0.89–1.31] 1.15 [0.68–1.76]
  Hazard ratio, crude 1.00 Reference 1.08 [0.90–1.31] 1.17 [0.90–1.31]
  Hazard ratio, adjusteda 1.00 Reference 1.07 [0.89–1.31] 1.11 [0.66–1.86]
rs1800629 −308GG −308GA −308AA
 All episodes of malaria
  n 477 104 3
  Incidence 2.97 (1216/409.2) 3.08 (282/91.5) 0.36 (1/2.8)
  Hazard ratio, crude 1.00 Reference 1.04 [0.87–1.24] 0.13 [0.02–0.63]
  Hazard ratio, adjusteda 1.00 Reference 1.10 [0.93–1.29] 0.14 [0.04–0.48]
 First episode of malaria
  Incidence 2.89 (392/135.6) 3.27 (91/27.8) 0.53 (1/1.9)
  Incidence ratio 1.00 Reference 1.13 [0.90–1.44] 0.18 [0.00–0.98]
  Hazard ratio, crude 1.00 Reference 1.07 [0.86–1.33] 0.27 [0.03–2.86]
  Hazard ratio, adjusteda 1.00 Reference 1.14 [0.91–1.44] 0.33 [0.03–3.59]
Page 7 of 11Gichohi‑Wainaina et al. Malar J  (2015) 14:249 
genotype was associated with a decrease in these rates 
may be due to the fact that these variants tag differ-
ent casual variants. This is indicated by the fact the two 
variants are not in linkage disequilibrium as well as no 
haplotype blocks were identified. A haplotype analysis 
previously conducted observed that many variants in 
TNF are inept markers of each other to the point that 
if one variant in TNF was a true disease susceptibility 
locus, most of the other variants in TNF would appear 
neutral [26]. This suggests that the disease associations 
with TNF variants are independent of each other. It may 
be reasonable to expect that TNF variants, in weak link-
age disequilibrium with each other, will also be in weak 
linkage disequilibrium with more distant variants in the 
central major histocompatibility class. This is because 
the strength of linkage disequilibrium is determined by 
among others the physical proximity of two mutations 
and proximity in time and lineage [27]. These factors are 
further modified by the effects of genetic drift, migration, 
and natural selection [28, 29]. So it is plausible that TNF 
variants, while inefficient markers of each other, may be 
good markers of variants in more distant genes that have 
different disease associations.
Findings described here add to the growing but con-
flicting evidence that allele variants of the TNF gene are 
associated with susceptibility to malaria [9, 30, 31]. Sev-
eral factors can explain apparent discrepancies in results 
obtained thus far in various studies. First, studies con-
ducted have varied in design. Most studies compared 
hospitalized cases of severe malaria with hospital- or 
community-based controls [9, 30, 32, 33]. Such studies 
can be implemented quickly and at a relatively low cost, 
but they are inherently vulnerable to selection bias if the 
distribution of TNF allele variants differs between cases 
and controls in the absence of a true association between 
these allele variants and malaria. As a consequence, for 
studies that recruited controls from a hospital setting, the 
strength of the association between TNF allele variants 
and malaria will be underestimated if these controls suf-
fered from a condition that is associated with TNF geno-
type. This is plausible, because TNF genotypes have also 
been associated with a variety of disorders other than 
malaria [34–37]. A better approach is to select controls 
that are representative of the population that produced 
the cases. Clark et al. [9] selected as controls cord blood 
samples obtained from birth clinics in the same hospi-
tal from which they recruited cases of severe malaria. 
Even so, bias may still have occurred in that study if TNF 
genotypes varied in frequency of delivery in hospital, or 
in the frequency of care-seeking behaviour and hospital 
admission for severe malaria. Such differentials may have 
occurred, for example, if the geographical distribution of 
TNF genotypes in relation to the hospital is uneven, or if 
TNF genotypes vary in the risk of birth complications. In 
addition, it is difficult to rule out that the results of TNF 
genotyping performed by Clark et al. in cord blood may 
have been affected by maternal DNA originating from 
contamination of cord blood at birth by maternal cells 
or by contact with maternal blood or tissue [38]. In this 
cohort study, bias may have occurred if there was dif-
ferential loss to follow-up such that the risk of being lost 
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Figure 1 Associations of TNF genotype with time to first episode 
of malaria. Values indicate the number of children, by TNF genotype 
group, who had remained free of malaria at 0, 100, 200, 300, and 
400 days of follow‑up. For TNF−1031 (rs1799964) allele variant (top 
panel), pairwise group comparison with the wild type genotype as 
the reference group yielded p‑values of 0.78 and 0.74 for heterozy‑
gotes rs1799964 TC and homozygotes (rs1799964 CC), respectively; 
for the TNF−308 allele variant (bottom panel), corresponding p‑values 
for heterozygotes (TNF−308GA) and homozygotes (TNF−308AA) were 
0.54 and 0.31, respectively (Peto tests). For homozygotes of the 
TNF−308A allele (TNF−308AA), the curve is not shown because only one 
episode occurred at 400 days of follow‑up.
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to follow-up was related both to malaria and TNF geno-
type, or if there were group differentials in the detection 
of malarial episodes. However, loss to follow-up was very 
low (3%), genotyping was successful for almost all (95%) 
children, and the study is believed to have captured virtu-
ally all malaria cases [39].
Secondly, both false positives (type I errors) and false 
negatives (type II errors) may occur especially among 
studies including relatively small numbers of subjects. 
Indeed our study had small numbers compared to studies 
that have previously been conducted to investigate these 
kind of associations. Due to this deficiency, this study 
may have had reduced chance of detecting a true effect 
due to low power. Furthermore, the likelihood that the 
statistically significant results reflect a true effect may be 
in question. To try and reduce the possibility of sample 
size affecting study conclusions we have avoided other 
possible sources of bias by having rigorous genotyping 
quality measures as well as diagnosis of P. falciparum 
malaria.
Thirdly, the relationship between TNF genotype and 
susceptibility to malaria may depend on population-
specific factors. For example, as noted in the introduc-
tion, TNF allele variants that are associated with an 
enhanced TNF response to chronic or repeated infec-
tions can possibly protect against newly acquired Plas-
modium infections through an altered iron metabolism. 
Such protection is conceivably more effective in chil-
dren who already have marginal iron status than in their 
iron-replete peers, and in children who are frequently 
exposed to infection. There may also be population-
specific masking of gene variant effects (epistasis) or 
gene–environment interactions specific to certain pop-
ulations. Additionally, haplotype heterogeneity between 
populations studied may exist. It has been proposed that 
the causal allele variants regulating TNF responses may 
actually be located downstream of the TNF gene and 
that TNF allele variants considered are in linkage dise-
quilibrium with the causal variant in some populations, 
but not in others [9]. Much of the literature investigat-
ing the issue of whether TNF promoter polymorphisms 
have any functional effect on TNF transcription or 
influence disease susceptibility appears to report nega-
tive results, emphasizing the conclusion that polymor-
phisms at this locus are functionally silent and exist only 
due to linkage disequilibrium with selectable human 
leukocyte antigen (HLA) alleles. Due to this, recent 
studies have increasingly included more markers in the 
HLA classes. The relevance of HLA antigens to disease 
is well recognized [40, 41] and may account for many 
of those studies that find positive evidence of associa-
tion to TNF. This emphasizes the role of TNF variants 
as markers for HLA or other disease loci located in the 
major histocompatibility class (MHC) [42, 43]. Several 
studies conducted within the African population have 
found associations between HLA alleles and P. falci-
parum malaria [44–46]. It is important to note that 
differences in the distribution of HLA alleles could be 
a cause of variation in associations between TNF poly-
morphisms and P. falciparum malaria in different geo-
graphical areas. With the increasing evidence of HLA 
associations with malaria, it may well be that TNF−1031 
and TNF−308 are not functional variants but markers of 
causal variants located elsewhere.
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Conclusion
In pre-school Tanzanian children living in an area of 
intense transmission, the TNF−1031CC genotype was 
associated with increased rates of malarial episodes, 
whereas the TNF−308AA genotype was associated with 
decreased rates. Further studies are needed to confirm 
these findings. Additionally, further studies considering 
associations with the wider MHC should be conducted 
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so as to identify candidate functional variants associated 
with severity of malaria.
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